TARS Stock Overview
A commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Tarsus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$54.70 |
| 52 Week High | US$57.14 |
| 52 Week Low | US$18.99 |
| Beta | 1.04 |
| 1 Month Change | 4.29% |
| 3 Month Change | 69.40% |
| 1 Year Change | 170.12% |
| 3 Year Change | 125.29% |
| 5 Year Change | n/a |
| Change since IPO | 165.79% |
Recent News & Updates
Tarsus Pharmaceuticals: Early Rollout Exceeding Expectations
Dec 10US$65.33 - That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results
Nov 16
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41%
Nov 07Recent updates
Tarsus Pharmaceuticals: Early Rollout Exceeding Expectations
Dec 10US$65.33 - That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results
Nov 16Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41%
Nov 07Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money
Nov 05Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable
Sep 05Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
Aug 20With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For
Jun 26Following Up On Tarsus Pharmaceuticals
May 28Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results
May 11Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
Mar 08Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic
Mar 03Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 01Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Nov 12What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates
Aug 16Shareholder Returns
| TARS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.5% | 1.3% | 0.6% |
| 1Y | 170.1% | 7.9% | 23.7% |
Return vs Industry: TARS exceeded the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: TARS exceeded the US Market which returned 23.7% over the past year.
Price Volatility
| TARS volatility | |
|---|---|
| TARS Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TARS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TARS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 244 | Bobby Azamian | www.tarsusrx.com |
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.
Tarsus Pharmaceuticals, Inc. Fundamentals Summary
| TARS fundamental statistics | |
|---|---|
| Market cap | US$2.10b |
| Earnings (TTM) | -US$134.34m |
| Revenue (TTM) | US$129.62m |
16.1x
P/S Ratio-15.6x
P/E RatioIs TARS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TARS income statement (TTM) | |
|---|---|
| Revenue | US$129.62m |
| Cost of Revenue | US$58.93m |
| Gross Profit | US$70.69m |
| Other Expenses | US$205.03m |
| Earnings | -US$134.34m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.51 |
| Gross Margin | 54.53% |
| Net Profit Margin | -103.64% |
| Debt/Equity Ratio | 30.2% |
How did TARS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 00:18 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tarsus Pharmaceuticals, Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |
| Jason Matthew Gerberry | BofA Global Research |